EUSA Pharma announce acquisition of SYLVANT® from Janssen
EUSA Pharma acquires SYLVANT from Janssen for $115 million
BioIVT acquires Optivia Biotechnology
BioIVT, a provider of research models and services for drug development, has announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its...
Sanofi and Advent finalise negotiations for the acquisition of Zentiva
Sanofi and Advent International (Advent) have finished negotiations for the acquisition of Zentiva - Sanofi's European generics business. Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion...
Takeda ups bid to $65 billion in negotiations to buy Shire
Takeda has increased offer to buy Shire for a mix of stock and cash worth ~$65 billion
Merck to sell Consumer Health to Procter & Gamble
Merck has sold its global Consumer Health business to Procter & Gamble
Advent in negotiations to acquire Sanofi’s generics business
Advent and Sanofi are in negotiations under which Advent would acquire Zentiva,
Certara acquires Analytica Laser
Certara announced it has acquired Analytica Laser which uses health economics and outcomes research (HEOR)
Mylan partners with Fujifilm Kyowa Kirin Biologics
Mylan partners with Fujifilm Kyowa Kirin Biologics to commercialise a biosimilar to Humira®
GSK buys out Novartis’ stake in Consumer Healthcare
GlaxoSmithKline plc have announced that it has reached an agreement with Novartis for the buyout of Novartis’ 36.5% stake in their Consumer Healthcare Joint...
Nanologica & Sterling partnership furthers new business venture
Nanologica AB has entered into a service agreement with global contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions for the large-scale production of...
Latest articles
Mind the Generation Gap in pharma marketing and market research
Industry came together to explore the impact of the generation gap in pharma marketing and market research at BHBIA's summer event. Different generations have always...
AstraZeneca presents anifrolumab results from Phase III TULIP trial
Results from the positive Phase III TULIP 2 trial for AstraZeneca's anifrolumab, a potential new medicine for the treatment of moderate to severe systemic...
Novartis advanced breast cancer treatment approved in Scotland
Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...
Popular articles
NHS Commercial Framework for Medicines consultation published
NHS England has published the NHS Commercial Framework for Medicines for consultation. NHS England has a significant role to play in supporting patient access to...
Mapping NHS change is key to customer engagement
Simon Grime, of Wilmington Healthcare, explains how mapping NHS change through data and intelligence can help industry understand and engage customers in the new...
Pf Power List 2019: Who is shaping the pharma & healthcare sector?
The Pf Power List has looked at who is making a difference in pharma and healthcare in 2019. This year has brought a range of developments...
Medopad and Janssen collaborate on novel digital biomarker for Alzheimer’s disease
Medopad has announced a strategic collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to validate, scale and...
Novartis advanced breast cancer treatment approved in Scotland
Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...